Vascular Disease Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Vascular Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 227 trials

Recruiting
Phase 3

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting

Technical Development of Cardiovascular Magnetic Resonance Imaging

Cardiovascular Disease
National Heart, Lung, and Blood Institute (NHLBI)3,400 enrolled2 locationsNCT04927429
Recruiting
Not Applicable

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

Cardiovascular Diseases
AstraZeneca3,000 enrolled69 locationsNCT06909773
Recruiting

Diabetes and Heart Disease Risk in Blacks

ObesityCardiovascular DiseasesHypertension+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,000 enrolled1 locationNCT00001853
Recruiting
Not Applicable

Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

Diabetes MellitusCardiovascular DiseasesHypertension+2 more
Medtronic Vascular130 enrolled19 locationsNCT07115953
Recruiting

BLOOM: Biological Legacy of Origin in Mother-Infant Dyads

Cardiovascular DiseasesChronic Kidney Diseases
University of Miami300 enrolled1 locationNCT02000895
Recruiting
Not Applicable

Improving Health Outcomes With Kefir

Cardiovascular DiseasesDiabetes Mellitus, Type 2Systemic Inflammatory Response
University of Alberta156 enrolled1 locationNCT06695221
Recruiting
Not Applicable

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1

Peripheral Vascular Diseases
Virginia Commonwealth University720 enrolled1 locationNCT04916327
Recruiting
Phase 1Phase 2

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

TumorCardiovascular DiseasesPulmonary Fibrosis+3 more
Peking Union Medical College Hospital30 enrolled1 locationNCT07464132
Recruiting
Not Applicable

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

Heart FailureCardiovascular DiseasesHeart Diseases
BrioHealth Solutions, Inc.780 enrolled32 locationsNCT06310031
Recruiting
Phase 3

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Cardiovascular DiseasesDiabete Type 2
Montreal Heart Institute10,000 enrolled39 locationsNCT05633810
Recruiting

AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices

Cardiovascular DiseasesHeart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Reduced Ejection Fraction (HFrEF)+2 more
University of Salerno205 enrolled1 locationNCT06909682
Recruiting
Not Applicable

Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure

Cardiovascular Diseases
Linkoeping University750 enrolled12 locationsNCT05641662
Recruiting

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

HypertensionCardiovascular DiseaseAdrenal Gland Neoplasm+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,150 enrolled1 locationNCT03374215
Recruiting
Phase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled565 locationsNCT07241390
Recruiting

Pulmonary Hypertension in Left Heart Disease

Pulmonary HypertensionPulmonary Vascular DiseaseLeft Heart Disease
Mayo Clinic3,000 enrolled1 locationNCT05935605
Recruiting
Not Applicable

SPYRAL GEMINI Pilot Study

Diabetes MellitusCardiovascular DiseasesHypertension+2 more
Medtronic Vascular175 enrolled13 locationsNCT06907147
Recruiting
Phase 2Phase 3

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Not Applicable

Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A)

HypertensionCardiovascular Disease
NYU Langone Health1,140 enrolled3 locationsNCT06485700
Recruiting

Natural History Study of CADASIL

Arterial StiffnessCardiovascular DiseaseGermline Mutation in the NOTCH 3 Gene+2 more
National Heart, Lung, and Blood Institute (NHLBI)155 enrolled1 locationNCT05072483